FIELD: medicine.
SUBSTANCE: group of inventions refers to medicine and is intended for treatment of schizophrenia. New derivatives of fatty acids are used, in particular (-)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]heptanoic acid, (+)-isopropyl-(Z)-7-[(1R,2R,3R,5S)-3,5-
dihydroxy-2-(3-oxodecyl)cyclopentyl]hept-5-enoate or (E)-7-[(1R,2R)-2-(4,4-difluoro-3-oxooctyl)-5-oxocyclopentyl]hept-2-enoic acid or the functional derivative of one of them.
EFFECT: group of inventions allows to expand the arsenal of means for treating schizophrenia of mammalian subjects.
7 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR TREATING TUMOUR | 2010 |
|
RU2577700C2 |
| NEW PROSTAGLANDIN DERIVATIVE | 2017 |
|
RU2748837C2 |
| PURGATIVE AGENT COMPOSITION | 2001 |
|
RU2278666C2 |
| LAXATIVE AGENT COMPOSITION | 2001 |
|
RU2694361C2 |
| NEW COMPOSITIONS AND METHODS FOR THEIR STABILIZATION | 2000 |
|
RU2275368C2 |
| NEW COMPOSITIONS AND METHODS FOR THEIR STABILIZATION | 2000 |
|
RU2695274C2 |
| SUBSTITUTED CYCLOPENTANS POSSESSING PROSTAGLANDIN ACTIVITY | 2008 |
|
RU2481339C2 |
| METHOD AND COMPOSITION FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | 2006 |
|
RU2440338C2 |
| SUBSTITUTED PHENYLSULFONAMIDE INHIBITORS OF BETA-AMYLOID SECRETION | 2003 |
|
RU2321394C2 |
| SUBSTITUTED CYCLOPENTANES, POSSESSING PROSTAGLANDIN ACTIVITY | 2009 |
|
RU2505530C2 |
